UAMY Plunges 25% as Antimony Price Crash Forces Steep Guidance Cut

What happened

United States Antimony shares fell 25% to $4.92 on Wednesday after the company slashed its full-year 2026 revenue guidance to $60–$75 million from $125 million, citing plunging antimony prices. The revision confirms a bearish driver already flagged in the company's August 11 8-K filing, but the market's sharp repricing signals that investors are now fully absorbing the deteriorating price environment. Background financials show the damage: Q2 gross margin collapsed to 7% from 27% a year earlier, first-half antimony gross profit fell 78%, and inventory ballooned to $21.6 million from $12.5 million in six months. While UAMY still holds a $248 million sole-source DLA contract and $57.3 million in cumulative government orders, actual Q2 recognized revenue was only $2.6 million due to acceptance timing slipping into July. The stock now trades below the previous 'attractive entry' zone of $5.25, reflecting heightened skepticism about the company's ability to convert backlog into earnings amid falling metal prices.

Implication

The 25% decline does not automatically create a buying opportunity because the underlying problem—low antimony prices and weak operating leverage—persists. If Q3 government revenue comes in at the guided $9–$10 million and gross margin improves above 15%, the stock could rebound toward the base-case value of $6.90, but that requires execution evidence not yet in hand. Conversely, if prices remain depressed and inventory conversion stalls, the bear-case value of $4.40 or lower becomes more likely, leaving limited downside cushion even after today's drop. The market is now pricing in a higher probability of the bear scenario, so a position should be sized for further downside rather than average-down without new data. Existing holders should treat the next quarterly filing as the decisive catalyst and use any rally toward $5.50–$6.00 to reduce risk.

Thesis delta

The thesis shifts to a more cautious stance as the confirmed guidance cut and falling antimony prices validate the bear-case driver and erode the margin of safety. The probability of the bear scenario increases from 30% to approximately 40%, while the base-case probability declines, lowering the expected value. However, with the stock at $4.92, below the previous attractive entry, the risk/reward improves slightly for patient investors awaiting Q3 proof, but the burden remains on the company to demonstrate acceptance and margin recovery before any upgrade.